Thomas Werfel, MD, from Hannover Medical School, Hannover, Germany, gives an overview of a phase 2a proof-of-concept clinical trial evaluating ZPL-3893787 (ZPL-389) for the treatment of moderate-to-severe atopic dermatitis in adults. The trial outcomes to date are presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016, held from 11-15 June in Austria, Vienna.
This content is supported by Ziarco Pharma Ltd.
EAACI is an independent organisation and cannot, therefore, endorse medicines or products.
